1. Home
  2. VTGN vs ARAI Comparison

VTGN vs ARAI Comparison

Compare VTGN & ARAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.27

Market Cap

25.3M

Sector

Health Care

ML Signal

HOLD

Logo Arrive AI Inc.

ARAI

Arrive AI Inc.

HOLD

Current Price

$0.26

Market Cap

20.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTGN
ARAI
Founded
1998
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Diversified Commercial Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
25.3M
20.4M
IPO Year
2014
2024

Fundamental Metrics

Financial Performance
Metric
VTGN
ARAI
Price
$0.27
$0.26
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$0.90
$12.00
AVG Volume (30 Days)
2.8M
542.7K
Earning Date
06-16-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$113,250.00
Revenue This Year
$124.49
$800.66
Revenue Next Year
$353.99
$650.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$0.22
52 Week High
$5.14
$6.86

Technical Indicators

Market Signals
Indicator
VTGN
ARAI
Relative Strength Index (RSI) 43.49 39.39
Support Level $0.21 $0.22
Resistance Level $0.32 $0.30
Average True Range (ATR) 0.02 0.03
MACD 0.01 0.01
Stochastic Oscillator 44.89 52.62

Price Performance

Historical Comparison
VTGN
ARAI

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

About ARAI Arrive AI Inc.

Arrive AI Inc is a technology company. Its patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox-whether by drone, ground robot, or human courier. The platform provides real-time tracking, smart logistics alerts, and advance chain-of-custody controls to support shippers, delivery services, and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots, and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting, and security systems to streamline the entire last-mile delivery experience.

Share on Social Networks: